Neoadjuvant and concurrent luteinising hormone-releasing hormone agonist (LHRHa) therapy is recommended for 3 to 6 months in men receiving radical radiotherapy for locally advanced prostate cancer. Adjuvant hormonal therapy in addition to radical prostatectomy is not recommended, even in men with margin-positive disease, other than in the context of a clinical trial 10 . Adjuvant hormonal therapy is recommended for a minimum of 2 years in men receiving radi- cal radiotherapy for locally advanced prostate cancer who have a Gleason score of ≥ 8. Bisphosphonates should not be used for the prevention of bone metastases in men.
